Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension
- Peter Nordbeck
- Ozlem Goker-Alpan
- John A. Bernat
- Dominique P. Germain
- Pilar Giraldo
- Ana Jovanovic
- Virginia Kimonis
- Kathleen Nicholls
- Cheryl Rockman-Greenberg
- Raphael Schiffmann
- Mark Thomas
- Anna Tylki-Szymanska
- Eric Wallace
- Richard W. D. Welford
- Michael L. West
- Martine Clozel
- Aline Frey
- Luba Trokan
- Markus S. Mueller
- Markus Vogler
- Christoph Wanner
- Derralynn Hughes
2026-01-10